January 3, 2019
A small feasibility study conducted by the Children’s Hospital of Philadelphia suggests that Project: Evo, the digital medicine developed by Akili Interactive Labs that is delivered via a video game, continually engaged children with autism spectrum disorder (ASD) and reduced their ADHD symptoms, although more objective measures of cognitive control were mixed.
Nineteen children aged...
January 3, 2019
This morning Otsuka America, a subsidiary of the Japanese pharma company, announced that it is teaming up with Click Therapeutics, maker of software as a prescription medical treatment, to create a new digital therapeutic to treat major depressive disorder (MDD).
The goal of the partnership is to develop a software app that will employ cognitive therapy principles and can be used either with or...
November 20, 2018
reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April.
But while physical prescription drugs are usually handled through a pharmacy, the process...
The digital health landscape, from the Digital Therapeutics Alliance's new report.
October 31, 2018
The precise definition of digital therapeutics has been a hot topic as the new technology category has been discussed and debated in event sessions and articles over the last few years. Now the Digital Therapeutics Alliance, a consortium of industry stakeholders, is hoping to put that to rest with an official definition, released this week in a whitepaper.
The definition reads as follows:
October 15, 2018
Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics.
On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...
October 15, 2018
As digital therapeutics move to cross boundaries of regulatory approval and efficacy data, the healthcare industry will begin to move to a bifurcated world of digital health apps in the same way that drugs are now divided up into largely unregulated supplements and heavily regulated pharmaceuticals.
At the Digital Health Innovation Summit last week in Boston, Sanofi Ventures Senior Director of...
September 12, 2018
Digital therapeutics maker Akili Interactive Labs today announced a deal with the University of California’s governing board concerning exclusive licensing of a new technology that will combine the company’s focus on neural systems with physical activity.
Developed at the Neuroscape Lab at UCSF, the tech follows in the footsteps of Akili’s other efforts in that it is primarily delivered through a...
Photo credit: RX.Health/Mt. Sinai
September 5, 2018
Rx.Health — a Mount Sinai Health System spinoff that has built an app prescription platform for enterprises — has raised $1.8 million in seed funding. According to a statement, the investment will help the company pursue new clients and support the launch of its digital therapeutics and patient engagement tool, Bulk Prescription.
"We've seen a tremendous increase in the demand for our services...
August 23, 2018
Dthera Sciences, a San Diego-based developer of clinical and consumer digital therapeutics for individuals with neurodegenerative conditions, announced today that its development stage intervention, DTHR-ALZ, has been granted Breakthrough Device designation by the FDA.
As laid out in the 21st Century Cures Act, the Breakthrough Devices Program looks to streamline new medical technologies that...
August 20, 2018
A recent small study published in Nature’s Translational Psychiatry journal observed a change in the brain networking and behavior of boys receiving a video game-based treatment for ADHD.
Conducted in Singapore, the study was conducted as part of a larger controlled investigation of boys with ADHD. It compared an intervention group of 18 participants (mean age 9 years) to a control arm of 11...